Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its Oncology Pipeline

 Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its Oncology Pipeline

Astrazeneca Expands Existing Deal with Innate Pharma to Strengthen its Oncology Pipeline

Shots:

  • AZ gains complete rights to monalizumab (Anti-NKG2A), also gains option rights to IPH5201 as well as 4 preclinical immuno-oncology molecules
  • Innate gains US and EU rights of Lumoxiti approved for HCL in addition to $100m for monalizumab, $50M for IPH5201 (Anti-CD39 mAb) and $20M for 4 preclinical molecules as upfront payment in H1’19 and additional milestones and royalties
  • AZ will receive $50M upfront and $25M as milestone along with 9.8% equity in Innate
  • The profit sharing of above cross-licensing deal will be done equally b/w the companies. IPH5201 is a CD39 mAb and Lumoxiti is a novel CD22-directed cytotoxin indicated for r/r HCL in the US

Click here to read full press release/ article | Ref: AstraZeneca | Image: Livemint

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post